Updated September 2026 - factual correction: this page previously stated that injectable GHK-Cu "remains on compounding Category 2 and cannot currently be compounded." That is no longer accurate. GHK-Cu was categorised by route, and the 2026 action removed each route from its respective category, with the Category 2 removals taking effect 23 April 2026. Corrected throughout, with the point that Category 1 is not approval stated plainly.

Updated September 2026: still no final rule on the first docket: the six peptides recommended in July 2026 are not on the final 503A Bulks List and HHS sign-off is outstanding, so the second meeting is queued behind a process that has not moved. Injectable GHK-Cu remains on compounding Category 2 today [superseded: see the correction note above], and the Melanotan II safety flag has been made explicit.

Recap in brief: what the July 2026 vote did and didn't do

On 23–24 July 2026, the FDA's Pharmacy Compounding Advisory Committee met and voted on a first tranche of peptides being considered for the 503A bulk drug substances list. The committee recommended that BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax move toward the affirmative list, and it declined to recommend emideltide (also called DSIP).

It is worth being precise about what that meeting was. PCAC is an advisory committee. Its recommendations are non-binding on the FDA. A favourable vote is one input into a longer process - it is not an approval, and it does not by itself make a substance legal to compound. Formal rulemaking still has to follow before anything changes in practice. In other words, the July vote moved the conversation forward; it did not settle it.

We covered the outcome and its limits in more detail in the FDA peptide vote results. This piece is about what appears to come next.

The five on the second docket

According to legal trackers and law-firm summaries following the July meeting, the FDA signalled a second PCAC meeting - expected before the end of February 2027 - to review five additional peptides. Taken together, the two meetings address twelve of the nineteen peptides placed in Category 2 in 2023: a phased, compound-by-compound review, not a blanket reversal, with each substance assessed individually against the 503A criteria. The FDA has not published a stated reason for splitting the review across two sittings. Here they are, with one honest line each on what the compound is and what regulatory lane it sits in. This is a plain-language reference, not an efficacy claim.

Of the five, two - injectable GHK-Cu and Melanotan II - are the ones most likely to surface in Looksmaxxing conversations, which is precisely why they warrant careful, non-hyped framing. Appearing on a review list is not a quality signal, a safety clearance, or a buying cue.

Correction: what actually happened to GHK-Cu's category

Earlier versions of this page, and a good deal of the library around it, said that injectable GHK-Cu sits on compounding Category 2 and cannot currently be compounded. That statement was accurate under the framework in place when it was written. It is not accurate now, and the reason it went stale is worth understanding, because the detail that resolves it is the detail almost everyone drops.

GHK-Cu was never categorised as a single substance. It was categorised by route.

• Injectable GHK-Cu sat in Category 2 - substances raising significant safety concerns.
• Non-injectable (topical) GHK-Cu sat in Category 1.

The 2026 action removed each route from its respective category. The Category 2 removals took effect 23 April 2026, following a Federal Register notice published 16 April 2026. So the injectable form came off Category 2, and the topical form came off Category 1, in the same sweep - which is why summaries that treat GHK-Cu as one item end up contradicting each other depending on which route their source was describing.

On the size of that sweep, two figures are in circulation and they do not match. The 27 February 2026 announcement by HHS Secretary Robert F. Kennedy Jr. described roughly 14 of 19 peptides moving. FDA's actual published action covered 12 peptides removed from Category 2. Rather than pick a side, the accurate summary is the one both figures support: the Category 2 list was cleared of most of the peptides on it.

Category 1 is not approval. It is not even close.

This is the sentence that matters most on this page, so it gets its own line.

Coming off Category 2, being reviewed for the 503A list, and FDA approval are three entirely different things. Category 1 status is a statement about where a substance sits in a compounding framework - nothing more. It carries no validated indications, no standardised dosing, no established safety record and no established efficacy record. A substance can sit in Category 1 and have no completed human trials behind it at all. Reading a category change as a clinical green light is the single most common error in this story.

And what replaced the old Category 2 position is not permission - it is a pending review. GHK-Cu goes in front of the second PCAC meeting. That meeting has not happened, no date for it has been posted, and the committee that will hold it is advisory. The honest status line is: previously restricted, now unrestricted-in-that-specific-sense, currently queued for scrutiny, still not approved for anything.

A calibration point, updated September 2026. The six peptides the committee did recommend in July 2026 are a useful benchmark for how little a docket appearance means. Note first that FDA's own career scientists recommended against adding any of the seven, citing insufficient evidence, and that the committee recommended six anyway - on confirmed margins of 8–6 with one abstention for BPC-157, KPV and TB-500 each, 7–4 with one abstention for Epitalon and 8–5 with one abstention for Semax. Emideltide (also called DSIP) was rejected 6-7 with one abstention (six in favour, seven against). That is a divided panel, not a consensus. And as of 19 October 2026, the FDA has published no proposed rule on them, none of the six is on the final 503A Bulks List, and no interim enforcement policy has been issued (one has been sent for White House review; see below). Notice-and-comment rulemaking is still required, and the Secretary of Health and Human Services must still formally approve any addition - neither has happened. Rulemaking realistically runs into 2027. Nearly three months after a favourable vote, nothing has been finalised. The five substances on this page are two full steps further back - they have not been voted on at all, and the second meeting is queued behind a process that is still stalled at step one.

October 2026: an interim policy whose coverage is unknown

On 14 October 2026 HHS and the FDA submitted a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs at the White House Office of Management and Budget. As of 19 October 2026 it is pending review, has not been issued, and its text is not public. Which substances, routes and conditions it covers is unknown. Press coverage has linked it to popular peptides such as BPC-157, which was among the six recommended in July; nothing published so far says it reaches the five peptides on this page, and readers should not assume GHK-Cu, LL-37, Dihexa, Melanotan II or PEG-MGF are included. Law firms expect, if issued, a form of temporary enforcement discretion for 503A pharmacies, which would approve nothing, add nothing to the 503A Bulks List, and could be withdrawn without notice-and-comment.

What "on the docket" actually means

This is the part that gets distorted fastest in social feeds, so it is worth stating plainly.

On the docket = scheduled to be reviewed. A peptide's presence on the second PCAC agenda means the committee is expected to examine the evidence for it. That is the beginning of a review, not the conclusion of one.

Reviewed is not recommended. The committee can review a compound and decline to recommend it - that is exactly what happened with DSIP in July.

Recommended is not approved. Even a favourable PCAC recommendation is advisory. The FDA is not bound by it, the HHS Secretary must still formally approve any addition to the list, and formal rulemaking has to follow before compounding status actually changes.

Approved is not "legal to buy today." None of the above turns a research compound into a consumer product you can lawfully purchase.

And critically: the FDA has not posted a final date, time, or comment docket for the second meeting. "Before the end of February 2027" is the current expectation reported by legal trackers, not a fixed calendar entry. The five-compound list and the timing should both be re-verified against the FDA's primary notice once it is published.

The safety asterisk

Being on a review list is not an endorsement - and Melanotan II is the clearest illustration of why that distinction matters.

Melanotan II is a non-selective melanocortin-receptor agonist - it does not act on one receptor subtype in isolation, which is the structural reason its effects are not confined to pigmentation. It carries a documented adverse-effect profile, it is widely sold through unregulated channels with no identity or purity assurance, and it has been the subject of long-standing dermatological concern about changes to pigmented lesions (moles) as well as health-authority warnings in multiple jurisdictions. Anyone with existing moles or a personal or family history of skin cancer should treat that as a clinical conversation, not an internet one.

Being on a docket is not a safety finding. Its appearance on a review list does not mean it is safe, close to approval, or advisable. It means the committee is expected to look at the evidence - including, presumably, the safety signals. A neutral reader should treat "it's on the list" and "it's a good idea" as entirely separate questions.

We are flagging this deliberately. When a headline reads "GHK-Cu and Melanotan are next," the implicit suggestion is momentum toward availability. That framing is misleading. A docket is a queue of things to be scrutinised, not a shortlist of things about to be sold. For a compound with a real safety record, the review is arguably the point - not a formality to be waved through.

What we'll be watching

Between now and the second meeting, a few concrete signals will tell the real story better than any headline:

The FDA primary notice. The official Federal Register announcement will confirm - or correct - the date, the time, and the exact list of compounds. Until it posts, everything is expectation.

The comment docket. The FDA has indicated a public comment docket will be published. What gets submitted, and by whom, is part of the record.

The FDA staff briefing materials. Ahead of PCAC meetings, staff typically release briefing documents summarising the evidence. These are usually the most substantive read available.

The eventual vote - and what follows it. As with July, a vote is advisory. The step that actually changes anything is rulemaking, and that comes later.

We will update this page against the primary notice when it appears. If you see a date circulating before the FDA posts one, treat it as provisional.

Frequently asked questions

Are these five peptides about to become legal? No. Being on the second PCAC docket means they are scheduled to be reviewed. Review is not recommendation, recommendation is not approval, and approval-to-compound requires formal FDA rulemaking that has not happened. Nothing about docket placement makes a compound legal to purchase.

When is the second PCAC meeting? The current expectation, per legal trackers, is before the end of February 2027. The FDA has not posted a final date, time, or comment docket. The date should be re-verified against the FDA's primary notice when it is published.

Does "on the docket" mean a peptide is approved? No. It means it is queued for review. The committee can review a compound and decline to recommend it - as it did with DSIP in July 2026 - and even a favourable recommendation is non-binding on the FDA.

Is Melanotan II safe because it's on the list? No - being on a docket is not a safety finding. Melanotan II is a non-selective melanocortin-receptor agonist with a documented adverse-effect profile, it is widely sold through unregulated channels, and there is long-standing dermatological concern about changes to pigmented lesions (moles). It has drawn health-authority warnings in several jurisdictions. Its presence on a review list means the evidence - including safety - is expected to be examined, not that it has been cleared.

Is injectable GHK-Cu still on compounding Category 2? No - and this page previously said otherwise. GHK-Cu was categorised by route: the injectable form sat in Category 2, the non-injectable (topical) form sat in Category 1. The 2026 action removed each route from its respective category, with the Category 2 removals effective 23 April 2026. The old statement was accurate under the earlier framework; it is not accurate now.

Does that mean injectable GHK-Cu is approved, or safe to use? No. Category 1 is not approval. It carries no validated indications, no standardised dosing, and no established safety or efficacy record. Coming off Category 2, being reviewed for the 503A list, and FDA approval are three different things, and GHK-Cu has only done the first. What replaced its old Category 2 position is not permission - it is a pending review in front of the second PCAC meeting, which has not happened and has no posted date. Any use is a conversation with a prescriber, not a conclusion drawn from a category change.

How many peptides came off Category 2? Two figures circulate. The February 2026 HHS announcement described roughly 14 of 19 peptides moving; FDA's published action covered 12 peptides removed from Category 2. The statement both support is that the Category 2 list was cleared of most of the peptides on it.

Related reading

• Do copper peptides work? What the evidence says
• Are peptides legal now? A 2026 status check
• Injectable GHK-Cu: the legal status explained
• The FDA peptide vote results, explained

Part of The Complete Guide to Looksmaxxing

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore GHK-Cu.

This article is educational content and not medical advice, and it contains no doses or protocols. Regulatory status is evolving; "reviewed" is not "recommended" or "approved," and the compound list and meeting date should be re-verified against the FDA's primary notice when posted. Claims for the Malaysian market are subject to MAB requirements.

References

• Mintz / National Law Review - "FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do."
• McDermott Will & Emery - coverage of the July 2026 two-day PCAC public meeting and the peptides recommended to the 503A list.
• Buchanan Ingersoll & Rooney - analysis of PCAC recommendations and the compounding rulemaking pathway.
• Orrick - "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting."
• Sheppard Mullin - "What to Watch: Status Update on Peptide Regulation."
• Newtropin - FDA peptide compounding status tracker (503A), for the reported second-meeting list and timing.
• Orrick (April 2026) and Pharmacy Times - GHK-Cu categorisation by route: injectable GHK-Cu in Category 2, non-injectable/topical GHK-Cu in Category 1; the 2026 action removed each route from its respective category. Category 2 removals effective 23 April 2026, per Federal Register notice published 16 April 2026.
• HHS announcement of 27 February 2026 described roughly 14 of 19 peptides moving; FDA's published action covered 12 peptides removed from Category 2. The two figures do not reconcile - prefer "the Category 2 list was cleared of most of the peptides on it," or state both with attribution.
• Category 1 is explicitly not approval: no validated indications, no standardised dosing, no established safety or efficacy record. Removal from Category 2, review for the 503A list, and FDA approval are three separate states.
• July 2026 PCAC: FDA's career scientists recommended against all seven substances; the committee recommended six. Confirmed margins: BPC-157 8–6 (one abstention), KPV 8–6 (one abstention), TB-500 8–6 (one abstention), Epitalon 7–4 (one abstention), Semax 8–5 (one abstention); emideltide (DSIP) rejected 6-7 (one abstention; six in favour, seven against). An earlier version of this file recorded TB-500's margin as unconfirmed; it is now confirmed. FDA identified no human safety studies for KPV, TB-500, MOTS-c or Epitalon. Sources: AJMC; NCPA (31 July 2026); Health Affairs Forefront; FDA briefing document; RAPS.
• PCAC votes are recommendations and are not binding on the FDA. Notice-and-comment rulemaking is still required, and the Secretary of Health and Human Services would still need to formally approve any addition. As of 19 October 2026 nothing has been added to the 503A Bulks List.
• Interim policy (October 2026): HHS/FDA submitted "Interim Access Policy for Compounding Using Certain Peptides" to OIRA/OMB for review on 14 October 2026; pending review, not issued, text not public as of 19 October 2026; covered substances unknown; likely mechanism enforcement discretion (law-firm analysis, not an FDA statement). Sources: Buchanan Ingersoll & Rooney (16 October 2026) https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know · Holland & Knight, "Peptides at a Crossroads" (October 2026) https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
• Second PCAC meeting (re-confirmed 19 October 2026): expected before the end of February 2027; no exact date has been posted, and the FDA has published no stated reason for splitting the review across two meetings - do not cite either until the FDA's primary notice appears. The two meetings together cover twelve of the nineteen peptides placed in Category 2 in 2023; each compound is evaluated individually against the 503A criteria.

Regulatory sources are secondary summaries. The FDA's Federal Register notice and PCAC meeting materials are the primary record and should be consulted directly when published.